Clinical Trials Browser

Bone Neoplasms, Sarcoma, Ewing, Osteosarcoma

NCT03793361 2026-03-18

EREMISS

Phase 2 Completed

127 enrolled

Sarcoma

NCT01900743 2026-03-13

REGO-SARC

Phase 2 Completed

219 enrolled

Sarcoma

Neoplasm Metastasis, Sarcoma

NCT04055220 2026-02-17

REGOSTA

Phase NA Recruiting

168 enrolled

Sarcoma

Pathologic Complete Response, Bone Neoplasms, Chondrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Patient Compliance, Sarcoma, Ewing, Osteosarcoma, Histiocytoma, Malignant Fibrous

NCT06820957 2026-02-17

Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body

Phase 2/3 Active not recruiting

437 enrolled

Sarcoma

Sarcoma, Ewing

NCT07379047 2026-01-30

GISTAR-1

Phase 2/3 Not yet recruiting

255 enrolled

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT06087263 2026-01-20

Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.

Phase 2 Active not recruiting

3 enrolled

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

Clinical Trials

Regbone

EREMISS

REGO-SARC

REGOSTA

Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body

GISTAR-1

Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.